Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index.
Schaefer M, Laurent V, Grandmougin A, Vuitton L, Bourreille A, Luc A, Clerc-Urmes I, Orry X, Frampas E, De Billy M, Pouillon L, Le Berre C, Gay C, Meyer J, Baumann C, Peyrin-Biroulet L. Schaefer M, et al. Among authors: bourreille a. Clin Gastroenterol Hepatol. 2022 May;20(5):e1040-e1049. doi: 10.1016/j.cgh.2021.06.035. Epub 2021 Jun 30. Clin Gastroenterol Hepatol. 2022. PMID: 34216820
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25. Gastroenterology. 2011. PMID: 21708105
Saccharomyces boulardii does not prevent relapse of Crohn's disease.
Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL, Marteau P, Rampal P, Moyse D, Saleh A, Le Guern ME, Galmiche JP; FLORABEST Study Group. Bourreille A, et al. Clin Gastroenterol Hepatol. 2013 Aug;11(8):982-7. doi: 10.1016/j.cgh.2013.02.021. Epub 2013 Mar 1. Clin Gastroenterol Hepatol. 2013. PMID: 23466709 Clinical Trial.
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease.
Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Fléjou JF, Carrat F; CESAME Study Group. Beaugerie L, et al. Among authors: bourreille a. Gastroenterology. 2013 Jul;145(1):166-175.e8. doi: 10.1053/j.gastro.2013.03.044. Epub 2013 Mar 27. Gastroenterology. 2013. PMID: 23541909
Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED).
Peyrin-Biroulet L, Bonnaud G, Bourreille A, Chevaux JB, Faure P, Filippi J, Laharie D, Vuitton L, Bulois P, Gonzalez F, Trang C, Koch S, Bernardini D, Cellier C; IBD Committee of the French Society of Digestive Endoscopy. Peyrin-Biroulet L, et al. Among authors: bourreille a. Endoscopy. 2013 Nov;45(11):936-43. doi: 10.1055/s-0033-1344783. Epub 2013 Oct 28. Endoscopy. 2013. PMID: 24165822 No abstract available.
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.
Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L. Bouguen G, et al. Among authors: bourreille a. Inflamm Bowel Dis. 2015 May;21(5):1047-53. doi: 10.1097/MIB.0000000000000359. Inflamm Bowel Dis. 2015. PMID: 25803504
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C, Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G, Fumery M, Nancey S, Roblin X, Altwegg R, Bouguen G, Bommelaer G, Danese S, Louis E, Zappa M, Mary JY; GETAID CREOLE Study Group. Bouhnik Y, et al. Among authors: bourreille a. Gut. 2018 Jan;67(1):53-60. doi: 10.1136/gutjnl-2016-312581. Epub 2017 Jan 24. Gut. 2018. PMID: 28119352 Free PMC article.
Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases.
Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bouguen G, Bourreille A, Ferrante M, Franchimont D, Frost K, Hebuterne X, Marshall JK, OʼShea C, Rosenfeld G, Williams C, Peyrin-Biroulet L. Ghosh S, et al. Among authors: bourreille a. Inflamm Bowel Dis. 2017 Mar;23(3):333-340. doi: 10.1097/MIB.0000000000001033. Inflamm Bowel Dis. 2017. PMID: 28146002 Free PMC article.
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission.
Reenaers C, Mary JY, Nachury M, Bouhnik Y, Laharie D, Allez M, Fumery M, Amiot A, Savoye G, Altwegg R, Devos M, Malamut G, Bourreille A, Flourie B, Marteau P, Vuitton L, Coffin B, Viennot S, Lambert J, Colombel JF, Louis E; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Reenaers C, et al. Among authors: bourreille a. Clin Gastroenterol Hepatol. 2018 Feb;16(2):234-243.e2. doi: 10.1016/j.cgh.2017.09.061. Epub 2017 Oct 7. Clin Gastroenterol Hepatol. 2018. PMID: 28993262 Free article.
130 results